First Clinical Research Stock Index (FCRI)

Market Activity

FCRI gained 7% last month, while pharmas gained 3%, biotechs gained 3%, and the   general market gained 2%. Seven FCRI stocks gained and two declined. There were two   significant gainers: INC Research Holdings (+25%) and ICON (+20%). There were no   significant decliners.

Notes on Indices    First Clinical Research Index (FCRI). Calculated as the mean average percentage   change from baseline, dividends excluded, adjusted for stock splits. In other words, the   indices are not weighted for stock price or market capitalization. Prices are in local   currencies. Index components may change from time to time based on new listings,   mergers and other factors. Components include eight publicly traded clinical research   stocks: CMIC (2309:JP), EPS Co., Ltd. (4282:JP), Hangzhou Tigermed Consulting Co Ltd   (300347:CH), ICON (ICLR:US), INC Research Holdings (INCR:US), Medidata   (MDSO:US), PAREXEL International (PRXL:US), PRA Health Sciences (PRAH:US), and   Quintiles Transnational Holdings (Q).    S&P 500 Index (SPX). Capitalization-weighted representative sample of 500 mostly   large-capitalization companies in leading industries of the U.S. economy.    S&P 500 Pharmaceutical Index (S5PHARX). Capitalization-weighted S&P 500   companies engaged in research, development or production of pharmaceuticals.    S&P 500 Biotechnology Index (S5BIOTX). Capitalization-weighted S&P 500   companies primarily involved in development, manufacturing or marketing of products   based on advanced biotechnology research.